De Novo device
DeepView AI® System
Spectralmd, Inc. · Software-Aided Adjunctive Diagnostic Device For Use By Healthcare Providers In Skin Wound Assessment. (SHY, Class II) · First FDA decision May 21, 2026, newest May 21, 2026BurnsChronic wounds and ulcers
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
2
Naming "DeepView AI"
MAUDE reports
0
Brand "DeepView AI", since 2015
PubMed studies
0
Mentioning "DeepView AI"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing DeepView AI® System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- DeepView AI® SystemNew device typeBreakthroughDe Novo
DEN250028 · Decided May 21, 2026 · 328 days after receipt
Device type: Software-Aided Adjunctive Diagnostic Device For Use By Healthcare Providers In Skin Wound Assessment. (SHY) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "DeepView AI", any status and sponsor, newest update first.
- Deepview HHF Training and Validation StudyNot yet recruiting
SpectralMDNot on our public-company list
NCT07677657 · 280 participants (planned) · Start Oct 5, 2026 · Primary completion Jun 1, 2027
Device: DeepView AI System · For: Burns; Burn Injury; Diagnostic
- Burn Validation StudyCompleted
SpectralMDNot on our public-company list
NCT06131203 · 274 participants · Start Dec 19, 2023 · Primary completion Mar 17, 2025
Device: DeepView SnapShot Portable (DV-SSP) · For: Burns; Wound Heal; Wounds and Injuries
Sites: Phoenix, Arizona; Sacramento, California; San Diego, California · 21 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "DeepView AI", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SHY
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "DeepView AI"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.